Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand.
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
05
2020
revised:
16
08
2020
accepted:
28
08
2020
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
3
10
2020
Statut:
epublish
Résumé
To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. This study included 124 eyes of 81 patients with retinoblastoma. Forty-three patients (53.1%) had bilateral retinoblastoma. The median age at diagnosis was 8 months (range, 1-48 months). Of 124 eyes, 9 eyes (7.3%) had extraocular retinoblastoma and 115 eyes (92.7%) had intraocular retinoblastoma, which were classified by the International Classification of Retinoblastoma (ICRB) as group A, 4 eyes (3.5%); group B, 19 eyes (16.5%); group C, 6 eyes (5.2%); group D, 31 eyes (27%); and group E, 56 eyes (47.8%). Treatment included systemic chemotherapy, intra-arterial chemotherapy, ruthenium-106 plaque brachytherapy, external beam radiation therapy, cryotherapy, transpupillary thermotherapy, subtenon chemotherapy, and intravitreal chemotherapy. At the median follow-up period of 38.4 months (range, 0.2-148.2 months), the overall globe salvage rate of intraocular retinoblastoma was 51.7%. For unilateral retinoblastoma, globe salvage rate was 37.5% (group B, 100%; group C, 100%; group D, 50%; and group E, 18.8%). For bilateral intraocular retinoblastoma, the globe salvage rate was 57.8% (group A, 100 %; group B, 94.4%; group C, 100%; group D, 64.7%; and group E, 28.2%). The overall survival rate was 93.8%. Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases.
Identifiants
pubmed: 33005446
doi: 10.1155/2020/4231841
pmc: PMC7508219
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4231841Informations de copyright
Copyright © 2020 Duangnate Rojanaporn et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest pertaining to the publication of this article.
Références
Pediatr Blood Cancer. 2012 Apr;58(4):545-50
pubmed: 21910211
Pediatrics. 2002 Mar;109(3):E45
pubmed: 11875173
Prog Retin Eye Res. 2019 Nov;73:100764
pubmed: 31173880
Med J Malaysia. 2010 Jun;65 Suppl A:128-30
pubmed: 21488473
Clin Exp Ophthalmol. 2005 Aug;33(4):386-9
pubmed: 16033351
BMC Pediatr. 2016 Apr 03;16:48
pubmed: 27038613
Saudi J Ophthalmol. 2017 Apr-Jun;31(2):80-85
pubmed: 28559718
Br J Ophthalmol. 2009 Sep;93(9):1129-31
pubmed: 19704035
Int J Ophthalmol. 2012;5(4):510-2
pubmed: 22937515
Br J Cancer Suppl. 1992 Aug;18:S8-12
pubmed: 1323994
Medicine (Baltimore). 2016 Oct;95(42):e5204
pubmed: 27759657
Pediatr Blood Cancer. 2017 Apr;64(4):
pubmed: 28221729
Ophthalmic Genet. 2011 Jun;32(2):122-5
pubmed: 21366428
J Med Assoc Thai. 1994 Aug;77(8):393-9
pubmed: 7876760
Clin Ophthalmol. 2014 May 20;8:993-7
pubmed: 24899796
Br J Ophthalmol. 2012 Aug;96(8):1078-83
pubmed: 22694968
J Pediatr Ophthalmol Strabismus. 2014 Jul 1;51(4):222-9
pubmed: 24844394
Pediatr Blood Cancer. 2006 Nov;47(6):801-5
pubmed: 16358310
Br J Ophthalmol. 2009 Jan;93(1):38-9
pubmed: 18838414
Br J Ophthalmol. 2016 Jun;100(6):839-42
pubmed: 26370121
Ophthalmology. 2006 Dec;113(12):2276-80
pubmed: 16996605
Br J Ophthalmol. 2011 Oct;95(10):1372-5
pubmed: 21252083
Ann Afr Med. 2011 Jul-Sep;10(3):214-9
pubmed: 21912005
Open Ophthalmol J. 2014 May 16;8:7-11
pubmed: 24949111
J Med Assoc Thai. 1993 Oct;76 Suppl 2:85-91
pubmed: 7823011
Jpn J Ophthalmol. 2009 Jan;53(1):35-39
pubmed: 19184307
J Pediatr. 1998 Mar;132(3 Pt 1):505-8
pubmed: 9544909
Br J Ophthalmol. 2016 Feb;100(2):172-8
pubmed: 26061162
Ophthalmic Epidemiol. 2014 Dec;21(6):406-11
pubmed: 25317653
Pediatr Hematol Oncol. 2007 Apr-May;24(3):221-31
pubmed: 17454793
Pediatr Hematol Oncol. 2019 Mar;36(2):73-81
pubmed: 30983466
S Afr Med J. 2014 Dec;104(12):859-63
pubmed: 26042269
Br J Ophthalmol. 2012 Aug;96(8):1084-7
pubmed: 22368262
Ophthalmology. 2011 Aug;118(8):1689, 1689.e1-6
pubmed: 21813093
Asian Pac J Cancer Prev. 2014;15(18):7863-7
pubmed: 25292078
J Pediatr Hematol Oncol. 2014 Aug;36(6):e335-40
pubmed: 24577551
Asian Pac J Cancer Prev. 2016;17(7):3515-9
pubmed: 27510002
Asian Pac J Cancer Prev. 2015;16(16):6899-902
pubmed: 26514464
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2683-91
pubmed: 16043839
Am J Ophthalmol. 2015 Dec;160(6):1116-1126.e5
pubmed: 26374932
Invest Ophthalmol Vis Sci. 2014 May 01;55(5):2816-21
pubmed: 24692122
Br J Ophthalmol. 2015 Jul;99(7):937-42
pubmed: 25583281
Asian Pac J Cancer Prev. 2011;12(9):2215-20
pubmed: 22296359
Arch Ophthalmol. 2001 Sep;119(9):1269-72
pubmed: 11545631
Asia Pac J Ophthalmol (Phila). 2019 May-Jun;8(3):211-217
pubmed: 30714357
Br J Ophthalmol. 2009 Jan;93(1):24-7
pubmed: 18718969
Neoplasia. 2018 Aug;20(8):757-763
pubmed: 29940303
J Pediatr Ophthalmol Strabismus. 2013 Mar-Apr;50(2):106-12
pubmed: 23244241
Asia Pac J Ophthalmol (Phila). 2014 May-Jun;3(3):151-7
pubmed: 26107585
Ophthalmol Clin North Am. 2005 Mar;18(1):65-73, viii
pubmed: 15763192
Asian Pac J Cancer Prev. ;18(2):421-424
pubmed: 28345824
Retina. 2019 Feb;39(2):379-391
pubmed: 29210937
J Pediatr Hematol Oncol. 2004 Jan;26(1):31-4
pubmed: 14707710
Arch Ophthalmol. 2004 May;122(5):729-35
pubmed: 15136321
J Fr Ophtalmol. 2015 Jun;38(6):535-41
pubmed: 25976136
Pediatr Blood Cancer. 2014 Sep;61(9):1610-5
pubmed: 24729462
Ghana Med J. 2010 Mar;44(1):10-5
pubmed: 21326985
Ophthalmologe. 2015 Mar;112(3):255-60
pubmed: 25378130
Ocul Oncol Pathol. 2018 Apr;4(3):170-175
pubmed: 29765949